Guardant Health: Great Execution, But At An Excessive Premium (NASDAQ:GH)
Guardant Health (GH) is seeing increased credibility for its Shield product, supported by Quest access and expanded coverage, alongside a strong oncology franchise. While the company's execution is strong and the stock has risen sharply, the author believes the current valuation premium is excessive. Consequently, the previous bullish stance has shifted to a more neutral outlook.
Guardant Health stock surges on colon cancer blood test news
Guardant Health's stock surged after UnitedHealth Group agreed to cover its Shield blood test for colon cancer as a first-line screening option for millions of members. This decision led Bernstein SocGen Group to raise its price target for Guardant Health to $200, highlighting a significantly expanded market for the company's leading cancer screening test. Despite the positive news and stock rally, analysts caution about the company's valuation, negative net margin, and insider selling, while anticipating further commercial insurer coverage and a formal USPSTF recommendation as future catalysts.
Guardant Health (GH) Is Up 12.6% After India Shield Cancer Test Deal And UnitedHealth Coverage Expansion
Guardant Health (GH) stock is up 12.6% following news of an exclusive agreement with Zydus Lifesciences to introduce its Shield Multi-Cancer Detection blood test in India, backed by Apollo Hospitals. This expansion, along with increased UnitedHealth coverage in the U.S., aims to broaden access to cancer screening. Despite these positive developments supporting the screening thesis, investors are cautioned about the company's significant cash burn and potential for future dilution.
Guardant Health (GH) CPO logs RSU vesting and $170.77 tax-withholding share transfer
Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of 4,020 restricted stock units (RSUs) on July 1, 2026. The company withheld 2,099 shares at $170.77 per share to cover tax obligations. Following these transactions, Ms. Monroe retains a significant holding of common shares and unvested RSUs.
Guardant Health (GH) CLO exercises RSUs as shares withheld for taxes
Guardant Health's Chief Legal Officer, John G. Saia, had 7,063 restricted stock units (RSUs) vest, converting into common stock on July 1, 2026. The company withheld 3,707 shares, valued at $170.77 per share, to cover tax obligations related to this vesting event. This transaction was compensation-related and did not involve open-market purchases or sales of shares.
Guardant Health (GH) director converts 155 RSUs into common shares
Guardant Health director Steve E. Krognes converted 155 Restricted Stock Units (RSUs) into common shares on June 30, 2026. This transaction represents a compensation-related vesting event and not an open-market purchase or sale. After the conversion, Mr. Krognes directly holds 14,580 shares of Guardant Health common stock.
Guardant Health (GH) CCO receives 7,414 shares from RSU vesting and tax withholding
Guardant Health's Chief Commercial Officer, Chris Freeman, received 7,414 shares through the vesting of restricted stock units (RSUs) on July 1, 2026. This transaction involved the conversion of RSU awards into common stock, with 3,141 shares withheld by the company to cover tax obligations at a value of $170.77 per share. The report clarifies that these were routine equity compensation and tax withholding events, not open-market purchases or sales.
Guardant Health stock rating reiterated at Buy by TD Cowen on UnitedHealth coverage
TD Cowen has reiterated a Buy rating and a $127.00 price target for Guardant Health (NASDAQ:GH) following UnitedHealth's decision to cover the Shield colorectal cancer screening test. This coverage, effective August 1, 2026, for average-risk individuals aged 45-85, is expected to expand Shield's addressable market by approximately 17%. While Guardant Health has a high revenue growth rate, it remains unprofitable, and several other analysts have also raised their price targets on the company.
Bernstein raises Guardant Health stock price target on UnitedHealth coverage
Bernstein SocGen Group increased its price target for Guardant Health (NASDAQ:GH) shares to $200 from $175, maintaining an Outperform rating. This follows UnitedHealth Group's decision to cover Guardant Health's Shield colorectal cancer screening test, a move expected to significantly boost the company's revenue estimates for 2030 and 2040. The stock saw a 19.5% jump and is up 240% over the past year, though InvestingPro analysis suggests it is currently overvalued.
Guardant’s Shield colon cancer blood test snags UnitedHealth coverage
Guardant Health's Shield test for colorectal cancer has secured coverage from UnitedHealth, marking the first time a major private U.S. health insurer will reimburse for the screening. This decision expands access to approximately 100 million Americans and is considered a "watershed moment" for liquid biopsy-based cancer screening. The Shield test is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults aged 45 and older, offering an alternative to stool-based tests.
Guardant Health (GH) files to resell 4,000 shares via cashless option exercise
Guardant Health (GH) has filed a Form 144 to resell 4,000 shares of common stock through a cashless employee option exercise on July 1, 2026. The filing also details recent open-market sales by Meghan V. Joyce in June 2026, totaling 20,203 shares across multiple transactions. These disclosures are administrative and do not imply material company-level effects.
Guardant Health Stock Climbs As Wall Street Targets Surge
Guardant Health (GH) stock surged after the FDA cleared its Guardant360 CDx as a companion test for a new HER2-mutant lung cancer drug, boosting investor optimism. Major Wall Street banks, including RBC Capital and Evercore ISI, initiated or upgraded coverage with significantly higher price targets, citing structural growth and anticipated volume increases. While insider sales were noted, executives retain substantial holdings, and the company's strong revenue growth and cash reserves support its high-growth, albeit currently loss-making, profile.
UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group has expanded its coverage to include Guardant Health’s Shield blood test for colorectal cancer (CRC) screening, making it the first major commercial insurer to do so for eligible members aged 45 or older. This policy update means over 100 million people now have access to the FDA-approved blood test, addressing rising CRC rates in younger populations. The Shield test, included in both ACS and NCCN guidelines, offers an accessible screening option through a simple blood draw.
UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group (UHG) now covers Guardant Health's Shield blood test for colorectal cancer (CRC) screening for eligible members aged 45 or older. This expansion by the largest commercial insurer in the U.S. makes the FDA-approved Shield test accessible to over 100 million covered lives. The Shield test is the first and only FDA-approved blood test included in both ACS and NCCN guidelines, offering a more accessible screening option amid rising CRC rates in younger populations.
Guardant Health options trading jumps to 2,617 contracts
Trading in Guardant Health Inc. options surged to 2,617 contracts by 1:20 p.m. New York time on Wednesday, with call volume at 1,001 contracts and put volume at 1,616 contracts. The August 21, 2026 $155 put was particularly active. Guardant Health shares experienced an 11.4% increase, trading at $167.11, while its three-month volatility and skew also saw changes.
Guardant Health Stock Rises As FDA And Wall Street Back Growth Story
Guardant Health (GH) stock saw a significant rise following FDA clearance of its Guardant360 CDx for a new HER2-mutant lung cancer drug, adding a 27th indication to its platform. This regulatory approval, coupled with bullish coverage from several prominent Wall Street firms like RBC Capital, Evercore ISI, Mizuho, Goldman Sachs, and Wolfe Research, has fueled investor confidence, driving the stock's momentum. Despite being a high-growth, loss-making company with negative operating margins and recent insider selling, its strong liquidity and multi-catalyst platform are repricing GH as a leader in precision oncology.
GH - Guardant Health Inc Options
This article provides a detailed financial overview of Guardant Health Inc. (GH), including its stock performance, key financial metrics, analyst recommendations, and insider activity. It highlights the company's valuation ratios, growth rates, and market statistics as of its last close on June 30.
Guardant Health (GH) co-CEO sells 260K shares after option exercises
Guardant Health co-CEO AmirAli Talasaz, through his family trust, sold 260,000 shares of common stock between June 26-29, 2026, at prices ranging from $150-$153 per share. Concurrently, Talasaz exercised stock options for 254,832 shares at an exercise price of $4.18 per share. The transactions are viewed as routine liquidity and portfolio management, resulting in a neutral signal for investors.
[Form 4] Guardant Health, Inc. Insider Trading Activity
Guardant Health's Chief Information Officer, Kumud Kalia, reported small, offsetting insider trades, including sales and purchases of common stock. After these transactions, Kalia directly holds 40,814 shares. A footnote indicated that the company identified and recovered $192 in Section 16(b) short-swing profits from Kalia.
Guardant Health Stock 5-Day Winning Spree: Stock Climbs 19%
Guardant Health (GH) stock has seen a significant surge, climbing 19% over the past five days. This performance highlights a strong winning streak for the company's shares.
Guardant Health Stock Surges 19%, With A 5-Day Winning Spree
Guardant Health (GH) stock has experienced a 19% surge over a five-day winning streak, increasing its market cap by $3.3 billion to $20 billion. Despite strong operating performance, the stock is considered "Relatively Expensive" due to its "Very High valuation." The article also details GH's returns against the S&P 500 over various periods and provides key financial data for the last two fiscal years and quarters.
Guardant Health, Inc.(NasdaqGS: GH) added to Russell Midcap Value Benchmark
Guardant Health, Inc. (NasdaqGS: GH) has been added to the Russell Midcap Value Benchmark. This update from S&P Capital IQ highlights the company's inclusion in this significant market index. The article also provides recent news on Guardant Health, including FDA approvals for its diagnostic products and insider stock transactions.
Guardant Health, Inc.(NasdaqGS: GH) added to Russell Midcap Growth Benchmark
Guardant Health, Inc. (NasdaqGS: GH), a precision oncology company, has been added to the Russell Midcap Growth Benchmark. This news highlights the company's growth and market recognition, following several recent positive developments including FDA approvals for its cancer diagnostic tests and favorable analyst ratings. The company focuses on genomics and AI analytics to improve cancer outcomes across all stages of care.
Guardant Health (GH) Stock After 193% One-Year Gain Is The Rally Running Out Of Room
Guardant Health (GH) has seen a 193% one-year gain, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is currently trading at a small 6.2% discount to its intrinsic value, indicating it is "about right" for its current price of $149. However, its Price/Sales (P/S) ratio of 18.32x is significantly higher than the industry average and Simply Wall St's Fair Ratio of 7.86x, suggesting the stock might be overvalued based on this metric.
Price to sales forward of Guardant Health, Inc. – NASDAQ:GH
This article provides the "Price to sales forward" metric for Guardant Health, Inc. (NASDAQ: GH). It is a brief financial data point from TradingView, highlighting the company's valuation. No specific values or periods are detailed in the provided content.
Price to earnings forward of Guardant Health, Inc. – NASDAQ:GH
This article provides the "Price to earnings forward" metric for Guardant Health, Inc. (NASDAQ: GH). It is presented as a financial data point without further analysis or context within the brief content, which primarily consists of navigation and boilerplate text from the TradingView platform.
GH (NASDAQ: GH) insider AmirAli Talasaz sells 260,000 shares totaling $28.1M
AmirAli Talasaz, an insider at Guardant Health (NASDAQ: GH), reported secondary sales of 260,000 common stock shares, totaling $28.1 million. The sales occurred in two separate transactions in May 2026, with the dispositions processed through Stifel Nicolaus & Company Inc. The SEC Form 144 filing also detailed existing holdings, including Founder Shares and shares from an equity compensation event.
[144] Guardant Health, Inc. SEC Filing
Guardant Health, Inc. (GH) filed a Form 144 with the SEC, notifying a proposed sale of 2,000 shares of common stock on June 26, 2026, related to an employee stock option exercise via a cashless broker payment. The filing also details previous dispositions by Meghan V. Joyce, including sales of 10,000, 6,203, and 2,000 shares on June 3, 2026, June 22, 2026, and June 24, 2026, respectively, with associated proceeds. Analysts view the filing as neutral, considering the proposed sale a routine mechanics-driven disposition and the insider dispositions as informational.
Guardant Health, Inc. Actuals & Estimates (DUS:5GH)
This article provides an overview of Guardant Health, Inc. (DUS:5GH) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It covers historical stock performance, future price forecasts from analysts, and details on upcoming earnings reports. The piece also addresses frequently asked questions about the company's stock, revenue, net income, dividends, and EBITDA.
Why Are Guardant Health (GH) Shares Soaring Today
Guardant Health (GH) shares rose 5.4% following positive ratings from several investment firms, including Bernstein SocGen Group, Goldman Sachs, and Wolfe Research. The positive sentiment is driven by the recent FDA approval of the company's G360 assay, which is expected to lead to broader insurance reimbursement. This recent surge follows a previous gain after its Guardant360 CDx liquid biopsy test also received FDA approval, reinforcing investor confidence in the company's growth prospects.
Guardant Health (GH) Is Up 8.5% After FDA OK For Guardant360 CDx Lung Test And Insider Sales – Has The Bull Case Changed?
Guardant Health's stock rose 8.5% following FDA approval for its Guardant360 CDx liquid biopsy test for HER2-mutant lung cancer. While this regulatory milestone reinforces the company's position in precision oncology, insider stock sales and ongoing financial losses introduce caution regarding financing and execution risks. Investors are encouraged to consider multiple viewpoints despite potential undervaluation and recent analyst upgrades.
Guardant Health (GH) Is Up 8.5% After FDA OK For Guardant360 CDx Lung Test And Insider Sales – Has The Bull Case Changed?
Guardant Health (GH) recently received FDA approval for its Guardant360 CDx liquid biopsy test for HER2-mutant lung cancer, leading to an 8.5% rise in its stock price. Despite this regulatory milestone, fresh insider selling and ongoing losses raise questions about financing and execution risks. The article suggests that while the approval strengthens Guardant's position in precision oncology, investors should consider diverse valuations and potential risks.
Form 144 Guardant Health For: 24 June By Investing.com
This article from Investing.com reports on a Form 144 filing for Guardant Health (GH) on June 24. The brief piece includes the stock symbol and mentions that Guardant Health's stock saw a 4.69% increase. No additional details about the Form 144 filing itself are provided.
Guardant Health (GH) Could Be 16% Below Fair Value On FDA Approval Win
Guardant Health (GH) recently received FDA approval for its Guardant360 CDx liquid biopsy, leading to strong stock momentum. While the widely followed analyst narrative suggests GH is 1% overvalued at $135.76, Simply Wall St's DCF model indicates it could be trading 16% below its estimated fair value of $162.43. The article highlights that future valuation hinges on factors like growth, profitability, and potential risks from R&D spending and reimbursement challenges.
Affiliate sells 2,000 shares via cashless exercise — Guardant Health (NASDAQ: GH)
An affiliate of Guardant Health (NASDAQ: GH) has filed a Form 144 to sell 2,000 common shares through a cashless exercise of employee stock options. The filing also disclosed prior sales by Meghan V. Joyce, totaling 10,000 shares for $1,269,809.00 on June 3, 2026, and 6,203 shares for $812,604.00 on June 22, 2026. This activity is considered a routine procedural notice to the market.
Guardant Health stock hits 52-week high at 135.89 USD
Guardant Health Inc. (GH) stock recently reached a 52-week high of $135.89, driven by strong investor confidence and significant revenue growth. The company has also received FDA approval for its Guardant360 CDx test and positive analyst ratings, although InvestingPro suggests it may be overvalued.
Guardant Health stock hits 52-week high at 135.89 USD By Investing.com
Guardant Health (GH) stock reached a 52-week high of $135.89, currently trading slightly below this peak at $135.12. This surge is attributed to strong investor confidence, a 165.83% 1-year change, and recent FDA approval for its Guardant360 CDx test. Several analyst firms have initiated or maintained Outperform/Buy ratings, further boosting its market position in cancer diagnostics.
Guardant Health director Myrtle Potter sells $204,084 in stock
Guardant Health director Myrtle S. Potter sold 1,556 shares of the company's common stock for approximately $204,084. This sale occurred while Guardant Health stock is trading near its 52-week high, following a 165% gain over the past year. Analysts maintain a positive outlook on the company, with several firms initiating or raising price targets due to recent FDA approvals and advancements in cancer screening.
Guardant Health director Tariq Musa sells $255,893 in stock
Guardant Health director Tariq Musa sold 1,951 shares of the company's common stock for $255,893 on June 22, 2026. This transaction occurred as the stock trades near its 52-week high and is considered overvalued by InvestingPro analysis. The sale follows recent positive developments for Guardant Health, including FDA approval for its Guardant360 CDx test and increased price targets from several analyst firms.
Guardant Health (GH) director sells 1,951 shares in open-market trade
Guardant Health director Tariq Musa sold 1,951 shares of common stock in an open-market transaction at an average price of $131.16 per share. Following this sale, Musa directly holds 11,048 Guardant Health shares, maintaining a significant equity position. The transaction was filed on Form 4 with the SEC, providing transparency on insider trading activity.
Form 4 Guardant Health Inc For: 23 June By Investing.com
This article provides a Form 4 filing for Guardant Health Inc. as of June 23, published by Investing.com. It briefly mentions the company's stock symbol GH and its daily stock performance. The content is primarily a placeholder for the actual Form 4 filing which is not detailed in the provided text.
Guardant Health (GH) director trims holdings with 1,556-share sale
Guardant Health director Myrtle S. Potter reported an open-market sale of 1,556 shares of Common Stock on June 22, 2026, at an average price of $131.16 per share, totaling $204,085. Following this transaction, she directly holds 20,971 Guardant Health shares. The filing was made public on June 23, 2026, and indicates a negative sentiment for the company.
Guardant Health (GH) director exercises RSUs, acquires 528 common shares
Guardant Health director Roberto Mignone has exercised Restricted Stock Units (RSUs), converting 528 RSUs into common shares through two transactions on May 21, 2026, and June 21, 2026, at a stated price of $0.00 per share. Following these transactions, Mignone directly holds 9,482 common shares and 7,392 RSUs. The RSU award, granted on November 8, 2024, vests over four years, with 25% having vested on October 21, 2025, and the remainder vesting monthly over the subsequent three years.
Form 144 Guardant Health For: 22 June By Investing.com
This article from Investing.com is a brief notice about a Form 144 filing for Guardant Health (GH) on June 22. It provides minimal information beyond the filing date and company, alongside general market data and other news headlines. The article includes the stock symbol GH and shows its recent performance.
Guardant Health (NASDAQ: GH) director gains shares as 4,203 RSUs vest and 2,711 new units granted
Guardant Health director Steve E. Krognes reported equity compensation activity where 4,203 Restricted Stock Units (RSUs) vested and converted into common stock on June 17, 2026. Following this, Krognes directly held 14,425 shares of Guardant Health common stock. On the same date, he also received a new grant of 2,711 RSUs, which will vest in full on June 17, 2027, or the company's next annual stockholder meeting.
Director Azar Alex M II receives 2,711 RSUs at Guardant Health (GH)
Guardant Health director Azar Alex M II was granted 2,711 Restricted Stock Units (RSUs) which will vest fully on June 17, 2026, or earlier if the company's next annual meeting occurs beforehand. These RSUs represent the right to receive one share of common stock for no cash payment upon vesting. After this transaction, Azar Alex M II directly holds 2,711 RSUs.
Guardant Health (GH) director Meghan Joyce gains 4,203 shares from RSU vesting
Guardant Health (GH) director Meghan V. Joyce received 4,203 shares of common stock from the vesting of restricted stock units on June 17, 2026, coinciding with the company's Annual Meeting of Stockholders. This transaction, a compensation-related event, increased her direct holdings to 15,386 shares. No open-market purchases or sales were associated with this filing.
Form 4 Guardant Health Inc For: 22 June By Investing.com
This article from Investing.com announces the filing of a Form 4 for Guardant Health Inc. on June 22. It is a brief, one-sentence notification, typical for automated financial news updates regarding SEC filings. The article also includes various market data and other news headlines.
Guardant Health (GH) director exercises 4,203 RSUs and receives 2,711-unit grant
Myrtle S. Potter, a director at Guardant Health (GH), recently exercised 4,203 Restricted Stock Units (RSUs) into common stock and received a new grant of 2,711 RSUs. Following these transactions on June 17, 2026, her direct holdings in Guardant Health common stock increased to 22,527 shares. The new RSU grant is set to vest fully on the earlier of one year from the grant date or the company's next annual meeting of stockholders.
Guardant Health (GH) director Mignone exercises 4,203 RSUs and receives 2,711-unit grant
Guardant Health director Roberto Mignone reported equity compensation activity, exercising 4,203 Restricted Stock Units (RSUs) into Common Stock and receiving a new grant of 2,711 RSUs on June 17, 2026. After these transactions, Mignone directly holds 8,954 shares of Common Stock. The exercised RSUs fully vested on June 17, 2026, the date of the 2026 Annual Meeting of Stockholders, while the new grant will vest on the earlier of its one-year anniversary or the next annual meeting.
